Angle Share Discussion Threads

[mark0419] 24/1/2023 13:06

Let everyone know what a fraudster you are.Google RICHARD DAVID BOBATH.look at this nonce called PATT. NO CREDIBILITY what so ever.

[mark0419] 24/1/2023 13:06

The fraudster called PATT.....purchaseatthetop.........Google RICHARD DAVID BOBATH.look at this nonce called PATT. NO CREDIBILITY what so ever.

[fevertreeman] 24/1/2023 12:00

You are quite right with your observations about investors vs traders. As an investor, I 'own' a stake in a company, and by making that investment I am making judgment calls on the board, the management, the strategy, the products, the markets etc. Many investors here feel angry about Selvey and Newland for the simple reason that having supported the Board over a long period of time, the company's share price is now back at its loweest level for 10 years! We feel we have been conned by the management and the Board

[kimchi1] 24/1/2023 11:40

As with all shares, I think there are traders here as well as investors (and people who do both!) - nothing wrong with some re-traces along the way, for now it seems we are seeing higher lows each time (since the start of this year), so perhaps the 'coiled spring' analogy is not so silly after all ...
Meanwhile CLSC in a week should be interesting to follow. Surely them and GFI showing an interest here is worth paying attention to more than a few bulletin board de-rampers ? But agreed that it's time the management started to deliver, I can see why longer term investors are not happy.

[1liam] 24/1/2023 11:03

Doctored FDA licence completion on twitter for USA. As if that makes any difference.

[parob] 24/1/2023 11:00

Meanwhile great news out of WANDisco this morning in which GFI has a 15% holding. Chart continues to break out.I wonder what their average buy in price is in AGL.

[fevertreeman] 24/1/2023 11:00

Couldnt agree more. It is truly shocking that Selvey is still in place as chair, given his woeful stewardship of the3 company over an extended period of time. It is equally shocking that he has not expressed any remorse, or concern about the direction of travel of the company that he chairs.

Only now is there a belated recognition within the BoD of what a mess they are in and how woefully underpowered and out of its depth they all are. Cue an unseemly scramble by Selvey to shore things up and deflect criticism of his woeful leadership with the scramble to onboard 2 NEDs who at least on paper bring much-needed financial and sector expertise. What have the board been doing these last few years, that they didnt recognise the crying need to freshen the board. Why on earth did Selvey leave this till after the share price has crashed? These appointments should have been made several years ago, and well in advanceof the final lap towards FDA approval...

[amaretto1] 24/1/2023 10:39

As a long term shareholder of AGL .... i feel I've been totally conned !!

[parob] 24/1/2023 08:27

This is an article from Nov 2022 so before they extended the deadline for investing, when CLSC was tipped by the Mail. It gives a good overview of the company/IPO. Fingers crossed they'll be successful. Just one week to find out now.hTTps://www.thisismoney.co.uk/money/investing/article-11471939/MIDAS-SHARE-TIPS-life-sciences-start-wealth-booster.htmlMIDAS SHARE TIPS: Why life sciences start-up could be a wealth booster - Conviction Life Sciences Company should make the grade

[letsbuy1] 23/1/2023 22:14

40p by FRIDAY LOAD UP LOAD UP

[astra1vision] 23/1/2023 21:24

Was it 50p last week or 40p suggested by LETSBUY1 before he vanished very embarrassingly, now punting his rubbish on other chats. Poor lad.

[letsbuy1] 23/1/2023 21:16

Astra being a c. U. N. T. On here i see.. standard for that werido

[astra1vision] 23/1/2023 18:47

In answer to PURCHASEATTHETOP, there should be newsflow announcing the death of AGL when the money runs out next year.

[fevertreeman] 23/1/2023 16:51

Another 1m shares traded today and no sign of any rally. Depressing stuff ; without concrete newsflow this is going nowhere

[fevertreeman] 23/1/2023 16:36

Not sure my comments disagree with your facts bar my silly mistake that 2022 revs were 500k short of expectations not in toto. In truth, AN does only have shortish window to get this going .....next 11 months...
- Cash burn in 2023 will be closely watched fig. Let's hope that cash is looked after
- 2023 Revenues...? Who knows? Does any one have any idea?
- Comercial contracts...7 months and counting

[parob] 23/1/2023 16:25

Exactly. Not long to find out now.In the meantime, the coil pattern on the chart is getting tighter. Should break out of it soon.

[kimchi1] 23/1/2023 15:54

Parob re: your post #17528

Just checked the shareprice of AGL on the date of that article - it was 107p
So at 31p the investment opportunity for them could be even more compelling now ?

[mrkeysersoze] 23/1/2023 12:26

fevertreeman
23 Jan '23 - 12:00 - 17536 of 17537
0 0 0
Indeed. May 25th last year FDA approval.....7 months on and counting and not a whiff of anything commercially consequential from Guildford.

Over last 10 years Newland has spent upwards of £100m developing Parsortix, banging the drum about how commercially fantastic this would be ......revenues 2022 £500,000, revenues in 2023 anyone's guess...Newland has a shortish window left to deliver some meaningful commercial news before he runs out of road.
------------------------------------------------------------------------------

Fevertreeman

FACT CHECK.......



"Cash at year end 2022 is expected to be in line with expectations at c. £32 million and the Company has no debt. Reported revenue for the year ended 31 December 2022 is expected to be just above £1 million, while operating loss for the year is estimated at c. £22 million and, excluding the one-off closure costs for Canada, is also in line with expectations. Approximately £0.5 million of revenue expected in 2022 is now expected to be recognised in 2023 due to delays outside the Company's control"



Mr K.

[parob] 23/1/2023 12:13

Paragraph from the 5/1/23 RNS:Encouragingly, the Company has already seen several new orders confirmed in the first week of January, which may reflect customers awaiting the start of their new budget year. The pipeline for both pharma and product sales remains strong and growing, with the Company's distributor network build out progressing as planned. The Company remains confident in the opportunities for the business, delivering on commercial milestones, building revenues and controlling costs.

[fevertreeman] 23/1/2023 12:00

Indeed. May 25th last year FDA approval.....7 months on and counting and not a whiff of anything commercially consequential from Guildford.

Over last 10 years Newland has spent upwards of £100m developing Parsortix, banging the drum about how commercially fantastic this would be ......revenues 2022 £500,000, revenues in 2023 anyone's guess...Newland has a shortish window left to deliver some meaningful commercial news before he runs out of road.

[purchaseatthetop] 23/1/2023 10:44

Kimchi.sorry hat I sound a little negative! I am long term holding and held after the FDA approval. Amateur mistake as always sell the news. I thought AN would have contracts ready in hand. Another amateur mistake!

[kimchi1] 23/1/2023 10:42

Preferably after the shareprice has exceeded 40p

[purchaseatthetop] 23/1/2023 10:30

The only question is when we get commencement of news flow.